JW (Cayman) Therapeutics Co (FRA:JNY) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:JNY JW (Cayman) Therapeutics Co Ltd FRA:JNY
16 GF Score
Price €0.18
GF Value €0.42
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is JW (Cayman) Therapeutics Co Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:JNY vs VRTX, REGN, ALNY: Short Interest Comparison

For the Biotechnology subindustry, JW (Cayman) Therapeutics Co's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

JW (Cayman) Therapeutics Co Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, JW (Cayman) Therapeutics Co's Short Interest distribution charts can be found below:

* The bar in red indicates where JW (Cayman) Therapeutics Co's Short Interest falls into.


FRA:JNY
16GF Score
JW (Cayman) Therapeutics Co Ltd FRA:JNY
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is JW (Cayman) Therapeutics Co (FRA:JNY) Overvalued in 2026?

Based on GuruFocus' analysis, JW (Cayman) Therapeutics Co stock appears to be undervalued. The current stock price of €0.18 is trading 58.1% below its estimated GF Value™ of €0.42. GuruFocus considers JW (Cayman) Therapeutics Co to be Possible Value Trap.

Key valuation signals for FRA:JNY:

  • Short Interest:
  • GF Value™: €0.42 vs. price of €0.18 (58.1% below fair value)
  • GF Score™: 16/100 with 3 warning signs

No single metric tells the full story. See the FRA:JNY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

JW (Cayman) Therapeutics Co Business Description

Other Exchanges JWCTF:USA02126:Hong Kong
Address No. 699 Zhong Ke Road, 5th Floor, Building B, Wison Center, Pudong New District, Shanghai, CHN
JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.
16GF Score

Get the complete analysis for FRA:JNY

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.18
Price
€0.42
GF Value